Olr788 inhibitors represent a class of chemical compounds that specifically interact with and modulate the activity of the Olr788 receptor, a member of the olfactory receptor family. These receptors, primarily recognized for their role in olfaction, are G protein-coupled receptors (GPCRs) that reside within the cell membrane and facilitate signal transduction through the activation of G proteins. Olr788, like other olfactory receptors, exhibits a unique structure characterized by seven transmembrane helices, which form a binding pocket for various ligands. Inhibitors targeting Olr788 typically function by binding to this receptor's active site or allosteric sites, preventing the receptor from interacting with its natural ligands. This inhibition can alter the receptor's conformation, effectively blocking the downstream signaling pathways initiated upon ligand binding.
The design and synthesis of Olr788 inhibitors involve sophisticated chemical methodologies aimed at achieving high specificity and affinity for the target receptor. These inhibitors often feature complex molecular frameworks that facilitate strong interactions with the receptor, such as hydrogen bonding, van der Waals forces, and hydrophobic interactions. Advanced techniques in computational chemistry and molecular modeling are employed to predict the binding modes and optimize the pharmacophoric features of these inhibitors. Additionally, various strategies such as high-throughput screening and structure-activity relationship (SAR) studies are used to identify potent compounds from large chemical libraries. By understanding the precise molecular interactions between Olr788 and its inhibitors, researchers can elucidate the underlying mechanisms of receptor function and inhibition, contributing to the broader field of receptor biology and chemical signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Inhibits mTOR, potentially impacting cell growth and proliferation. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR inhibitor, may disrupt epidermal growth factor signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Targets RAF kinases, might affect cell proliferation and angiogenesis. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK1/2 inhibitor, could modulate cytokine signaling and immune response. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Inhibits VEGFR, PDGFR, and KIT, potentially affecting angiogenesis and cell growth. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
BCR-ABL inhibitor, might affect leukemia cell proliferation and survival. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
BCL-2 inhibitor, could induce apoptosis in cancer cells. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
MEK inhibitor, may disrupt MAPK/ERK signaling affecting cell growth. | ||||||
Afatinib-d4 | 850140-72-6 (unlabeled) | sc-481821 | 10 mg | $4665.00 | ||
Irreversible EGFR inhibitor, potentially affecting cell proliferation in certain cancers. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Inhibits MET, VEGFR, and AXL, could influence cell survival and angiogenesis. | ||||||